Oculis Holding AG (OCS)

NASDAQ: OCS · Real-Time Price · USD
16.35
-0.98 (-5.65%)
At close: Aug 28, 2025, 4:00 PM
16.49
+0.14 (0.86%)
After-hours: Aug 28, 2025, 5:00 PM EDT
-5.65%
Market Cap855.69M
Revenue (ttm)960,668
Net Income (ttm)-135.09M
Shares Out 52.34M
EPS (ttm)-2.92
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume27,275
Open17.20
Previous Close17.33
Day's Range16.35 - 17.20
52-Week Range11.56 - 23.08
Beta0.12
AnalystsStrong Buy
Price Target35.75 (+118.65%)
Earnings DateAug 21, 2025

About OCS

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2003
Employees 49
Stock Exchange NASDAQ
Ticker Symbol OCS
Full Company Profile

Financial Performance

In 2024, Oculis Holding AG's revenue was 686,000, a decrease of -22.31% compared to the previous year's 883,000. Losses were -85.78 million, -3.41% less than in 2023.

Financial numbers in CHF Financial Statements

Analyst Summary

According to 4 analysts, the average rating for OCS stock is "Strong Buy." The 12-month stock price target is $35.75, which is an increase of 118.65% from the latest price.

Price Target
$35.75
(118.65% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Oculis to Participate in Upcoming September Investor Conferences

ZUG, Switzerland, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovative solutions for ophthalmic...

19 hours ago - GlobeNewsWire

Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D.

ZUG, Switzerland, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-op...

3 days ago - GlobeNewsWire

Oculis Reports Q2 2025 Financial Results and Provides Company Update

ZUG, Switzerland, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significan...

7 days ago - GlobeNewsWire

Oculis to Participate in Upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

ZUG, Switzerland, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-oph...

16 days ago - GlobeNewsWire

Oculis to Participate in Upcoming H.C Wainwright 5th Annual Ophthalmology Virtual Conference

ZUG, Switzerland, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-oph...

16 days ago - GlobeNewsWire

Oculis Upsized Loan Facility to Access up to CHF 100 million

ZUG, Switzerland, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthal...

27 days ago - GlobeNewsWire

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

ZUG, Switzerland, July 09, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to directors of the Company.

7 weeks ago - GlobeNewsWire

Oculis Publishes Results of 2025 Annual General Meeting

ZUG, Switzerland, June 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), today announced the results from its 2025 Annual General Meeting held on Ju...

3 months ago - GlobeNewsWire

Oculis to Participate in Upcoming June Investor Conferences

ZUG, Switzerland, June 03, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-...

3 months ago - GlobeNewsWire

Oculis Publishes Invitation to the Annual General Meeting

ZUG, Switzerland, May 09, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), today published the invitation to the 2025 Annual General Meeting, which will be held on Ju...

3 months ago - GlobeNewsWire

Oculis Reports Q1 Financial Results and Provides Company Update

ZUG, Switzerland, May 08, 2025 (GLOBE NEWSWIRE) -- The recent R&D Day ( replay) showcased material progress across all three core assets and highlighted potential first-in-class neuroprotection treat...

4 months ago - GlobeNewsWire

Oculis Reports Q1 2025 Financial Results and Provides Company Update

The recent R&D Day ( replay) showcased material progress across all three core assets and highlighted potential first-in-class neuroprotection treatment in neuro-ophthalmology, an area of high unmet ...

4 months ago - GlobeNewsWire

Oculis to Present at Upcoming May Investor Conferences

ZUG, Switzerland, May 07, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-o...

4 months ago - GlobeNewsWire

Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences

ZUG, Switzerland, May 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-o...

4 months ago - GlobeNewsWire

Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences

ZUG, Switzerland, May 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-o...

4 months ago - GlobeNewsWire

Oculis Updates Share Capital

ZUG, Switzerland, April 25, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company, has issued registered ordinary shares o...

4 months ago - GlobeNewsWire

Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award

ZUG, Switzerland, April 17, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro...

4 months ago - GlobeNewsWire

Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets

ZUG, Switzerland, April 15, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing ophth...

4 months ago - GlobeNewsWire

Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema

ZUG, Switzerland, April 10, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro...

5 months ago - GlobeNewsWire

Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema

ZUG, Switzerland, April 10, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro...

5 months ago - GlobeNewsWire

Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond

ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing ophth...

5 months ago - GlobeNewsWire

Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities

ZUG, Switzerland, March 20, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to trades entered into by a PDMR of the Company pursuant to a 10b5-1 trading plan, in accordance with Rule 10b5-1...

5 months ago - GlobeNewsWire

Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update

ZUG, Switzerland, March 11, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing ophth...

6 months ago - GlobeNewsWire

Oculis to Present at Upcoming March Investor Conference

ZUG, Switzerland, March 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care...

6 months ago - GlobeNewsWire

Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares

ZUG, Switzerland, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthal...

7 months ago - GlobeNewsWire